Alkermes (8AK) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

8AK Analyst Ratings

Moderate Buy

9 Buy

2 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

8AK Stock 12 Month Forecast

Average Price Target

€51.67

▲(22.65% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is €51.67 with a high forecast of €67.93 and a low forecast of €33.09. The average price target represents a 22.65% change from the last price of €42.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"€22","45":"€45","68":"€68","33.5":"€33.5","56.5":"€56.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67.9270917,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€67.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.671035566666674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€51.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.092685700000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,33.5,45,56.5,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.56,42.665160900000004,44.770321800000005,46.875482700000006,48.98064360000001,51.08580450000001,53.1909654,55.296126300000005,57.401287200000006,59.50644810000001,61.61160900000001,63.7167699,65.8219308,{"y":67.9270917,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.56,41.414695043589745,42.26939008717949,43.12408513076923,43.97878017435898,44.833475217948724,45.68817026153847,46.54286530512821,47.39756034871795,48.252255392307696,49.106950435897446,49.96164547948719,50.81634052307693,{"y":51.671035566666674,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.56,39.98559120769231,39.411182415384616,38.83677362307692,38.262364830769236,37.68795603846154,37.11354724615385,36.53913845384616,35.96472966153846,35.39032086923077,34.815912076923084,34.24150328461539,33.6670944923077,{"y":33.092685700000004,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.84,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.56,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€67.93

Average Price Target€51.67

Lowest Price Target€33.09

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

€53.99

Buy

28.16%

Upside

Reiterated

09/21/26

Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target

Douglas Tsao

H.C. Wainwright

€37.45

Hold

-11.12%

Downside

Reiterated

09/21/26

Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target

Akash Tewari

Jefferies

€62.7→€67.93

Buy

61.23%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), Twist Bioscience (NASDAQ: TWST) and Medpace Holdings (NASDAQ: MEDP)

Uy Ear

Mizuho Securities

€56.61

Buy

34.36%

Upside

Reiterated

09/04/26

Mizuho survey shows no consensus into Alkermes ADHD dataMizuho survey shows no consensus into Alkermes ADHD data

David Amsellem

Piper Sandler

€56.61

Buy

34.36%

Upside

Reiterated

08/06/26

Piper Sandler Remains a Buy on Alkermes (ALKS)

Jessica Fye

J.P. Morgan

€52.25→€53.12

Hold

26.09%

Upside

Assigned

07/29/26

Alkermes price target raised to $61 from $60 at JPMorganAlkermes price target raised to $61 from $60 at JPMorgan

Luke Herrmann

Robert W. Baird

€41.8→€50.51

Buy

19.89%

Upside

Reiterated

07/29/26

Alkermes price target raised to $58 from $48 at BairdAlkermes price target raised to $58 from $48 at Baird

Benjamin Burnett

Wells Fargo

€56.61

Buy

34.36%

Upside

Assigned

07/29/26

Wells Fargo Gives a Buy Rating to Alkermes (ALKS)

Jason Gerberry

Bank of America Securities

€33.09

Sell

-21.45%

Downside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Raffles Medical Group (Other OTC: RAFLF), IDEAYA Biosciences (NASDAQ: IDYA) and Alkermes (NASDAQ: ALKS)

Leonid Timashev

RBC Capital

€48.77

Buy

15.76%

Upside

Reiterated

07/28/26

RBC Capital Remains a Buy on Alkermes (ALKS)

Joseph Thome

TD Cowen

€49.64→€50.51

Buy

19.89%

Upside

Reiterated

07/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Matteis

Stifel Nicolaus

€39.19→€54.86

Buy

30.23%

Upside

Reiterated

07/25/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Celldex (NASDAQ: CLDX)

Ashwani Verma

UBS

€36.58→€41.8

Buy

-0.78%

Downside

Reiterated

05/06/26

Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

03/31/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Pete Stavropoulos

Cantor Fitzgerald

€37.45

Buy

-11.12%

Downside

Reiterated

03/11/26

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

€53.99

Buy

28.16%

Upside

Reiterated

09/21/26

Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target

Douglas Tsao

H.C. Wainwright

€37.45

Hold

-11.12%

Downside

Reiterated

09/21/26

Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target

Akash Tewari

Jefferies

€62.7→€67.93

Buy

61.23%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), Twist Bioscience (NASDAQ: TWST) and Medpace Holdings (NASDAQ: MEDP)

Uy Ear

Mizuho Securities

€56.61

Buy

34.36%

Upside

Reiterated

09/04/26

Mizuho survey shows no consensus into Alkermes ADHD dataMizuho survey shows no consensus into Alkermes ADHD data

David Amsellem

Piper Sandler

€56.61

Buy

34.36%

Upside

Reiterated

08/06/26

Piper Sandler Remains a Buy on Alkermes (ALKS)

Jessica Fye

J.P. Morgan

€52.25→€53.12

Hold

26.09%

Upside

Assigned

07/29/26

Alkermes price target raised to $61 from $60 at JPMorganAlkermes price target raised to $61 from $60 at JPMorgan

Luke Herrmann

Robert W. Baird

€41.8→€50.51

Buy

19.89%

Upside

Reiterated

07/29/26

Alkermes price target raised to $58 from $48 at BairdAlkermes price target raised to $58 from $48 at Baird

Benjamin Burnett

Wells Fargo

€56.61

Buy

34.36%

Upside

Assigned

07/29/26

Wells Fargo Gives a Buy Rating to Alkermes (ALKS)

Jason Gerberry

Bank of America Securities

€33.09

Sell

-21.45%

Downside

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: Raffles Medical Group (Other OTC: RAFLF), IDEAYA Biosciences (NASDAQ: IDYA) and Alkermes (NASDAQ: ALKS)

Leonid Timashev

RBC Capital

€48.77

Buy

15.76%

Upside

Reiterated

07/28/26

RBC Capital Remains a Buy on Alkermes (ALKS)

Joseph Thome

TD Cowen

€49.64→€50.51

Buy

19.89%

Upside

Reiterated

07/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Matteis

Stifel Nicolaus

€39.19→€54.86

Buy

30.23%

Upside

Reiterated

07/25/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Celldex (NASDAQ: CLDX)

Ashwani Verma

UBS

€36.58→€41.8

Buy

-0.78%

Downside

Reiterated

05/06/26

Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

03/31/26

Wall Street Analysts Are Neutral on Top Healthcare Picks

Pete Stavropoulos

Cantor Fitzgerald

€37.45

Buy

-11.12%

Downside

Reiterated

03/11/26

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

ZVRAZevra Therapeutics

IMUXImmunic

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

3 Months

Paul MatteisStifel Nicolaus

Success Rate

9/13 ratings generated profit

Average Return

+8.15%

Copying Paul Matteis's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.15% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

12/13 ratings generated profit

Average Return

+29.85%

Copying Paul Matteis's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +29.85% per trade.

2 Years

Paul MatteisStifel Nicolaus

Success Rate

12/13 ratings generated profit

Average Return

+32.71%

Copying Paul Matteis's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +32.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8AK Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 8AK has received 20 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. 8AK average Analyst price target in the past 3 months is 51.67.

Each month's total comprises the sum of three months' worth of ratings.

8AK Financial Forecast

8AK Earnings Forecast

Next quarter’s earnings estimate for 8AK is -€0.07 with a range of -€0.10 to >-€0.01. The previous quarter’s EPS was €0.00. 8AK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 8AK has Performed in-line its overall industry.

8AK Sales Forecast

Next quarter’s sales forecast for 8AK is €403.97M with a range of €387.53M to €419.60M. The previous quarter’s sales results were €431.95M. 8AK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 8AK has Performed in-line its overall industry.

8AK Stock Forecast FAQ

What is DE:8AK’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 51.67.

What is DE:8AK’s upside potential, based on the analysts’ average price target?

Alkermes has 22.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alkermes a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 2 hold ratings and 1 sell ratings.

What is Alkermes’s share price target?

The average share price target for Alkermes is 51.67. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €67.93 ,and the lowest forecast is €33.09. The average share price target represents 22.65% Increase from the current price of €42.13.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Alkermes?

To buy shares of DE:8AK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alkermes (8AK) Stock Forecast & Price Target

8AK Analyst Ratings

8AK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

8AK Analyst Recommendation Trends

8AK Financial Forecast

8AK Earnings Forecast

8AK Sales Forecast

8AK Stock Forecast FAQ

Detailed List of Analyst Forecasts